logo
Giant 85 million-year-old mystery sea monster fossil finally identified

Giant 85 million-year-old mystery sea monster fossil finally identified

Yahoo4 days ago

When you buy through links on our articles, Future and its syndication partners may earn a commission.
Scientists have finally solved the mystery behind the identity of a prehistoric sea monster.
The marine reptile, which could grow to around 39 feet (12 meters) long and had heavy teeth for crushing prey, was previously known from several sets of fossils unearthed over the past two decades.
One key fossil was a complete but badly-preserved adult skeleton from about 85 million years ago, discovered in 1988 on Vancouver Island in British Columbia, Canada. It was thought to come from a group of long-necked reptiles known as plesiosaurs. However, until now, scientists weren't sure if it belonged to a new species or a previously discovered one.
"The identity of the animal that left the fossils has remained a mystery," F. Robin O'Keefe, a professor of anatomy at Marshall University in West Virginia, said in a statement. "Our new research published today finally solves this mystery."
In a new study published May 22 in the Journal of Systematic Palaeontology, O'Keefe and colleagues formally classified all the fossils as Traskasaura sandrae. This species is so different from other marine reptiles that researchers assigned it to a brand new genus, Traskasaura, within a subgroup of plesiosaurs called elasmosaurs.
Elasmosaurs, like other plesiosaurs, lived throughout the Cretaceous period (145 to 66 million years ago) alongside the dinosaurs and shared the oceans with other marine reptiles, including ichthyosaurs and mosasaurs. Plesiosaurs were characterized by having small heads on long necks, broad bodies and four large, paddle-like limbs. The mythical Loch Ness Monster is usually depicted as a plesiosaur. They are thought to have breathed air and probably had to surface regularly, akin to modern-day marine mammals.
The first T. sandrae specimen was unearthed in 1988 in the Haslam Formation on Vancouver Island, was formally described by scientists in 2002 and dates back to between 86 and 83 million years ago. Other fossils found in the same region include a right humerus and an "excellently preserved" juvenile skeleton.
Related: Half-a-billion-year-old 3-eyed sea creature dubbed 'Mosura' breathed through big gills on its butt
Although the adult specimen discovered in 1988 wasn't quite different enough from other elasmosaurs, it wasn't similar enough to any known species either.
"Relatively few characters are unambiguous on this skeleton," the researchers wrote in their paper.
Newer fossils also had strange traits, but they weren't complete enough to confirm the possibility of a new species. The newest juvenile skeleton specimen, however, helped shed light on these ancient creatures' features, revealing that three had the same key traits.
"It has a very odd mix of primitive and derived traits — the shoulder, in particular, is unlike any other plesiosaur I have ever seen," said O'Keefe.
After analyzing the features of all three fossil specimens, the researchers concluded that they must all belong to a new genus of elasmosaur.
RELATED STORIES
—Ancient sea monsters grew their long necks super fast after Great Dying by adding more vertebrae
—Enormous 240 million-year-old sea monster had its head torn off in one clean bite
—Giant 'sea dragon' fossil could be largest mosasaur ever discovered in Mississippi
T. sandrae is thought to have at least 50 vertebrae in its neck. This adaptation may have made the aquatic predator extremely good at downward swimming and suggests that it hunted prey by diving from above.
What about their diet? The ammonite molluscs that were plentiful in the oceans during the Cretaceous period are a "good candidate — due to Traskasaura's robust teeth, ideal, possibly, for crushing ammonite shells," O'Keefe said.
"When I first saw the fossils and realized they represented a new taxon, I thought it might be related to other plesiosaurs from the Antarctic," said O'Keefe. "My Chilean colleague Rodrigo Otero thought differently, and he was right; Traskasaura is a strange, convergently evolved, fascinating beast."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting
CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting

Yahoo

time7 hours ago

  • Yahoo

CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting

SHANGHAI, June 1, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: a company focused on developing innovative CAR T-cell therapies, announces that the results of the pivotal Phase II clinical trial in China (CT041-ST-01, NCT04581473) investigating satricabtagene autoleucel ("satri-cel", CT041) (a Claudin18.2-specific autologous CAR T-cell product candidate) in patients with Claudin18.2-positive, advanced gastric/gastroesophageal junction cancer refractory to at least two prior lines of treatment, have been published in The Lancet and were orally presented at the 2025 ASCO Annual Meeting. Further details have been posted on the corporate website The article in The Lancet was titled "Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial". Full article available at: The oral presentation at the 2025 ASCO Annual Meeting (Abstract 4003) was titled "Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician's choice (TPC) for previously treated advanced gastric or gastroesophageal junction cancer (G/GEJC): Primary results from a randomized, open-label, phase II trial (CT041-ST-01)". Professor Lin Shen from Beijing Cancer Hospital, the principal investigator of this study, said, "The CT041-ST-01 trial represents the world's first randomized controlled clinical study of CAR-T cell therapy for solid tumors. In patients with heavily pretreated, advanced gastric/gastroesophageal junction cancer who have extremely limited treatment options and poor prognosis, satri-cel has demonstrated breakthrough efficacy with significant clinical benefits, including much improved progression-free survival (PFS), overall survival (OS), and tumor response rates. This brings new hope to patients with otherwise medically untreatable conditions. We are further exploring satri-cel's potential in adjuvant settings and as first-line sequential therapies, aiming to intervene earlier in the disease course, extend patients' survival, and ultimately pursue potential cures." Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics, said, "We are honored that the CT041-ST-01 study results were published in The Lancet—a premier, global medical journal—and presented at the 2025 ASCO Annual Meeting. The positive result of this randomized controlled trial marks a major milestone in solid tumor CAR-T therapy. These achievements are a testament to the whole research team's years of dedication, and we extend our deepest gratitude to patients and their families for their trust and participation. This year, satri-cel has been granted Breakthrough Therapy Designation and Priority Review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the treatment of Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) in patients who have failed at least two prior lines of therapy. We plan to submit a New Drug Application (NDA) for satri-cel to the NMPA this month and anticipate its approval as the world's first commercially available CAR-T product for solid tumors, bringing benefits to patients." About Satri-cel Satri-cel is an autologous CAR T-cell product candidate against the protein Claudin18.2 that has the potential to be the first-in-class globally. Satri-cel targets the treatment of Claudin18.2-positive solid tumors with a primary focus on G/GEJA and pancreatic cancer (PC). Initiated trials include investigator-initiated trials (CT041-CG4006, NCT03874897), a confirmatory Phase II clinical trial for advanced G/GEJA in China (CT041-ST-01, NCT04581473), a Phase Ib clinical trial for PC adjuvant therapy in China (CT041-ST-05, NCT05911217), an investigator-initiated trial for satri-cel be used as consolidation treatment following adjuvant therapy in patients with resected G/GEJA (CT041-CG4010, NCT06857786), and a Phase 1b/2 clinical trial for advanced gastric or pancreatic adenocarcinoma in North America (CT041-ST-02, NCT04404595). Satri-cel has been granted Priority Review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in May 2025. Satri-cel has been granted Breakthrough Therapy Designation by the CDE of China's NMPA for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in March 2025. Satri-cel was granted Regenerative Medicine Advanced Therapy designation by U.S. FDA for the treatment of advanced G/GEJA with Claudin18.2-positive tumors in January 2022. Satri-cel received Orphan Drug designation from the U.S. FDA in September 2020 for the treatment of G/GEJA. About CARsgen Therapeutics Holdings Limited CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen's mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable. Forward-looking Statements All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group's current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group's control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading "Principal Risks and Uncertainties" in our most recent annual report and interim report and other announcements and reports made available on our corporate website, No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release. Contact CARsgen For more information, please visit View original content to download multimedia: SOURCE CARsgen Therapeutics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Northern lights may be visible in these 23 US States tonight
Northern lights may be visible in these 23 US States tonight

Yahoo

time11 hours ago

  • Yahoo

Northern lights may be visible in these 23 US States tonight

When you buy through links on our articles, Future and its syndication partners may earn a commission. Northern lights could put on an impressive show tonight (June 1) as ongoing geomagnetic storm conditions may push auroras farther south than usual, according to the National Oceanic and Atmospheric Administration. Earth is currently reverberating from a speedy coronal mass ejection (CME) impact that struck in the early hours of June 1, wreaking havoc on our planet's magnetic field — great news for anyone hoping to see the northern lights. Space weather forecasters from the U.K. Met Office predict frequent G1 to G2 level storming and occasional G3 and even G4 level storm intervals possible June 1-2. Read more: Aurora alert: Ongoing powerful geomagnetic storm could spark more northern lights across the US tonight The NOAA Space Weather Prediction Center predicts that the Kp index will peak at 7.67 over the next 24 hours. For an up-to-date breakdown of timings, check out NOAA's 3-day forecast. (Kp is a measurement of geomagnetic activity, with an index that ranges from 0 to 9; higher Kp indicates stronger auroral activity.) Aurora chasers, get those cameras charged, fingers crossed and your eyes firmly fixed on the skies! You can also keep up with the latest forecasts and geomagnetic storm warnings with our aurora forecast live blog. Alaska has the highest chance of seeing the northern lights tonight. If G3 or even G4 storm levels are reached, auroras could be visible at high-latitude states, including Michigan and Maine, according to NOAA. Below, we have listed all 23 states that appear either fully or in part above the possible view line for auroras tonight according to NOAA's Space Weather Prediction Center. They are ordered most likely to least likely based on their proximity to the auroral oval's center and how much of each state is within or near the view line. But remember, auroras are fickle — sometimes they appear much farther south than predicted, and other times they barely show up at all. Many conditions have to align for the perfect display. Alaska Montana North Dakota Minnesota Wisconsin Michigan South Dakota Vermont New Hampshire Maine Idaho Washington Oregon New York Massachusetts Connecticut Rhode Island Nebraska Iowa Wyoming Illinois Indianna Pennsylvania If you find yourself in one of the 23 states forecasted to have a chance of seeing the northern lights tonight, head to a north-facing vantage point as far away from light pollution as possible. But as we approach the summer solstice on June 20/21, the window of darkness for observing northern lights is shrinking; the early morning hours around 1 and 2 a.m. might be the best time to try and see the northern lights. Interested in tracking space weather and knowing when and where to spot auroras? Download a space weather app that provides forecasts based on your location. One option I use is "My Aurora Forecast & Alerts," available for both iOS and Android. However, any similar app should work well. I also use the "Space Weather Live" app, which is available on iOS and Android, to get a deeper understanding of whether the current space weather conditions are favorable for aurora sightings. Editor's note: If you snap a great picture of the northern or southern lights and would like to share it with readers, send your photo(s), comments, and your name and location to spacephotos@

Google's AI push overshadowed by an awkward date error
Google's AI push overshadowed by an awkward date error

Yahoo

time13 hours ago

  • Yahoo

Google's AI push overshadowed by an awkward date error

When you buy through links on our articles, Future and its syndication partners may earn a commission. Google was all about AI at its annual I/O event last week. The tech giant wants its Gemini AI model everywhere and plans to put it in all of its devices. It also plans on bringing its AI into more of its services. One of those services getting the AI upgrade is Gmail. Over the course of the upcoming weeks, Gmail users will begin seeing AI summaries of their email, according to a blog post from Google. This summary will provide bullet points of what was in the email as well as any follow-up replies to make sure you're up to date. This feature will only be available on emails in English. Those who don't care for AI summarizing their correspondence can opt out of the feature, but it will be enabled by default. Google began instituting AI features into Gmail last year by having Gemini provide instant replies that no longer sounded generic. At the same time, Google is implementing new AI features, but some people have found the company's AI is far from perfect. A post on Reddit went viral earlier in the week when a screenshot of an interaction with an AI summary on Google Search was unable to determine what the current year was. And yet we can't turn this off from r/google In the screenshot, the individual did a Google search asking, "Is it 2025?" The AI summary they received apparently had issues with the question saying, "It is not 2025. The current year is 2024." Other people on X posted similar results. Wired did multiple tests over this prompt and confirmed the issue. In one case, the AI summary reiterated that it was 2024, but said that in parts of New Zealand and Russia, it was 2025. It even went on to contradict itself, saying that it was 2025 after claiming it was 2024. A Google spokesperson says it was working on the problem. 'As with all Search features, we rigorously make improvements and use examples like this to update our systems. The vast majority of AI Overviews provide helpful, factual information, and we're actively working on an update to address this type of issue,' Meghann Farnsworth, a Google spokesperson, told Wired. As of the publication of this article, Googling "is it 2025" returns with an AI summary saying, "Yes, according to the provided information, the current year is 2025." It remains to be seen if this problem will happen again in 2026. Google makes a bold pitch for an all-encompassing AI: "Project Astra" Google and XREAL announce Project Aura, XR smart glasses for Android An exclusive look at Google's NotebookLM app on Android and iOS

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store